UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________________________________________________

FORM 8-K

_______________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6 19, 2025

_______________________________________________________

PROTHENA CORPORATION PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

_______________________________________________________

Ireland

001-35676

98-1111119

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

77 Sir John Rogerson's Quay, Block C

Grand Canal Docklands

Dublin 2,

D02 VK60,

Ireland

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: 011-353-1-236-2500

___________________________________________________

(Former Name or Former Address, if Changed Since Last Report.)

___________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Ordinary Shares, par value $0.01 per share	PRTA	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in ~~as defined in~~ Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.0207. Submission ~~Results~~ of ~~Operations~~Matters ~~and~~to ~~Financial~~a ~~Condition~~Vote of Security Holders.

~~The~~On ~~information~~November in19, ~~Item 2.02~~2025, ofProthena ~~this~~Corporation ~~Current~~plc ~~Report~~(the ~~on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed~~ “~~filed~~Company”) ~~for~~held ~~purposes~~an ofextraordinary ~~Section 18~~general ofmeeting ~~the Securities Exchange Act~~ of ~~1934~~shareholders, asat ~~amended~~which (the ~~“Exchange~~Company’s ~~Act”),~~shareholders orvoted ~~otherwise~~on ~~subject to~~ the ~~liabilities~~following ofproposal, ~~that~~which ~~section.~~is Itdescribed ~~may only be incorporated by reference~~ in ~~another~~the ~~filing~~Company’s ~~under~~definitive ~~the~~proxy ~~Exchange~~statement ~~Act~~filed orwith the Securities ~~Act~~and ofExchange ~~1933,~~Commission ason ~~amended~~October 7, if2025: ~~such subsequent filing specifically incorporate by reference the information furnished pursuant to Item 2.02 (including Exhibit 99.1) of this Current Report.~~

OnProposal ~~November 6,~~No. ~~2025,~~1: ~~Prothena~~Approval ~~Corporation~~of ~~plc issued~~ a ~~press~~Reduction ~~release~~of ~~announcing~~the ~~its~~Company’s ~~financial~~Capital ~~results~~to ~~for~~Create ~~the~~Distributable ~~third~~Reserves. The ~~quarter~~shareholders ~~ended~~approved ~~September 30,~~a ~~2025.~~reduction ~~A copy~~ of ~~that~~the ~~press~~Company’s ~~release~~capital ~~is furnished as Exhibit 99.1~~ to ~~this~~create ~~Current~~distributable ~~Report on Form 8-K and is incorporated herein by reference~~reserves.

Item 9.01. Financial Statements and Exhibits


For	Against	Abstain
37,779,052	46,738	45,906

~~(d)~~ Item 9.01. Financial Statements and Exhibits.

Exhibit No.						Description
99.1						Press Release dated November 6, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

(d) Exhibits


Exhibit No.						Description
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:

November 619, 2025

PROTHENA CORPORATION PLC

By:

/s/ Tran B. Nguyen

Name:

Tran B. Nguyen

Title:

Chief ~~Financial~~Strategy Officer and Chief ~~Strategy~~Financial Officer

Filing Compare · PROTHENA CORP PUBLIC LTD CO